Drug intelligence / Profile preview

Levovirin

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Levovirin is a pharmaceutical drug classified as a guanosine nucleoside analogue and is the L-enantiomer of ribavirin. It is an investigational drug primarily developed for the treatment of chronic hepatitis C virus (HCV) infection. Levovirin exhibits immunomodulatory activity, similar to ribavirin, but notably lacks direct antiviral activity and causes less hemolytic anemia, which is a significant side effect of ribavirin. This improved safety profile was intended to offer a better therapeutic option for patients with chronic HCV.

Targets

TBEV NS3h (Nonstructural protein 3 (NS3))

Beyond the preview

Go deeper on Levovirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levovirin.

Explore the full profile